RXI Pharmaceuticals Corporation Unternehmenskultur

Dr. Geert Cauwenbergh, Ph.D., Dr., Med.Sc., has been the Chief Executive Officer and President of RXi Pharmaceuticals Corporation since April 27, 2012 and serves as its Acting Chief Financial Officer. Dr. Cauwenbergh serves as Scientific Advisor of Skin Care, Dermatology, Wound Care, OTC, Infectious Diseases, Women's Health at Q BioMed Inc. Dr. Cauwenbergh serves as Senior Advisor of Wombat Capital. Dr. Cauwenberghhas been the Head of International Advisory Board at Skinvisible Inc. since November 2008. He has been the Official Trade Advisor to the Belgian Government for Health Care in the USA since 2004. He served as Business Advisor of Edge Therapeutics, Inc., since June 2010. He has more than 20 years experience in international research, clinical drug development and new product commercialization for both specialty pharmaceuticals and anti-infectives at both pharmaceutical and biotechnology companies, including Johnson & Johnson (J&J) and the Janssen Research Foundation in Belgium. Dr. Cauwenbergh served as the Chief Executive Officer of RHEI Pharmaceuticals Inc., from August 1, 2008 to June 2011 and also served as its Chairman. He served as Managing Director of the Center for Medical Innovation, a government subsidized center for translational medicine for the Belgian Region of Flanders. Prior to joining RHEI Pharmaceuticals in February 2008, he was a founder and Chief Executive Officer of Phases123, LLC. He founded Barrier Therapeutics Inc. in September 2001 and served as its Executive Chairman from September 2001 to June 2006, Chief Executive Officer from September 2001 to March 31, 2008 and also served as its President. He founded Aramis LLC in May 2009. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. He served at Johnson & Johnson (in both the U.S. and Europe) Consumer and Personal Care Products Companies from 2000 to 2002, where he served as Vice President of Technology, where he created technology platforms based on intellectual property and know-how owned by it and developed a business proposition around these platforms as the basis for new companies or new businesses within or outside it. From 1994 to 2000, Dr. Cauwenbergh served as Global Vice President of Research & Development at Johnson & Johnson Consumer Companies Worldwide. He served as Vice President, Research and Development for Johnson & Johnson's Skin Research Center and was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. Dr. Cauwenbergh served as Vice President, Product Development and a Member of the Management Board of U.S. J&J Consumer Company since 1994. In his career, he served positions in sales and national and international marketing and he was responsible for the successful global introduction of Nizoral (ketoconazole). His R&D activities had also involved him in the fields of psoriasis, acne, wound healing, atopic dermatitis, protozoal infections and HIV. He served as an Executive Chairman at ECI Biotech. He serves as the Chairman of Expressive Constructs, Inc. He served as the Chairman of BioNJ Inc. Dr. Cauwenbergh served as the Chairman of Bio New Jersey from 2009 to 2010. He has been a Director of RXi Pharmaceuticals Corporation since April 2012. Dr. Cauwenbergh serves as a Member of the Board of Trustees at Bio New Jersey. He has been a Director of Cutanea Life Sciences Inc. since July 9, 2010. He has been a Director of Moberg Pharma AB (publ) (alternate name: Moberg Derma AB) since April 23, 2012. He serves as a Director of RHEI. He served as an Independent Director of Ablynx NV until April 25, 2013. He served as a Member of the Board of Intercept Inc. (US), from 2003 to 2005. He served as a Director of RealSource Residential, Inc. (Upstream Biosciences, Inc.) from March 25, 2008 to December 14, 2009. He served as a Director of Euroscreen S.A since July 2008. He served as an Independent Non Executive Director at Phosphagenics Limited since February 28, 2014 until May 2017. He served as a Director of Midatech Pharma US Inc. (DARA BioSciences, Inc.) from June 14, 2008 to April 4, 2009. He served as a Member of the Business Development Council at J&J. Dr. Cauwenbergh served in the R&D organization of the Janssen Research Foundation since 1982, where he served in positions of increasing global responsibility as an International Director of Clinical R&D, Dermatology and Infectious Diseases and oversaw development of drugs such as Sporanox, Nizoral Shampoo, Terazol and topical Sufrexa. He served as the Director of Corporate Skin Care Council of J&J, co-ordinating all skin care activities in the different operating groups of Corporation. From 2004 to 2006, he served as a Member on the Board of Trustees of the New Jersey Center of Life Sciences. He has authored over 100 publications and co-authored several books. In 2004, he was inducted into the New Jersey High Tech Hall of Fame. Dr. Cauwenbergh received his PhD in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, Belgium where he also completed his Masters and undergraduate work. He holds Bachelor's Degree and Master's Degree from Katholieke Universiteit Leuven. He is Fluent in English, French, German and Dutch.

Dr. Karen Bulock, Ph.D., serves as Vice President of Research at RXi Pharmaceuticals Corporation. Dr. Bulock joined Galena Biopharma, Inc. in October of 2007 and served as the Associate Director of Research until April 2012. Dr. Bulock has over twenty years of experience in assay development and discovery project management. Since joining RXi in 2011 and previously while at Galena, Dr. Bulock has managed several key programs, including the discovery and preclinical development of RXI-109, RXi's first clinical candidate. Prior to joining RXi, Dr. Bulock worked several years leading assay development and screening projects to support small molecule drug discovery programs in the fields of metabolic disease and anti-infectives at CytRx Corporation and Essential Therapeutics, Inc. Dr. Bulock has authored numerous scientific articles and is a co-inventor on four patent applications. Dr. Bulock received a Ph.D. in Pharmacology from Yale University.

Dr. Gerrit Dispersyn, Dr. Med. Sc, has been Chief Development Officer at RXi Pharmaceuticals Corporation since May 19, 2017. Dr. Dispersyn is the founder of Ingress, LLC, a consultancy company providing R&D and clinical operations support to start-up companies, supporting several pharmaceutical drug development programs. Dr. Dispersyn is an accomplished leader in clinical, product and business development. He served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporation. In this role, he was responsible for Integra's global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integra's Senior Management Leadership team and several of the company's core teams for M&A projects. Dr. Dispersyn has also been involved in Integra's research and business activities related to Human Cells, Tissues and Cellular and Tissue based Products (HCT/Ps), an experience that could be beneficial for RXi's newly added focus on immuno-oncology and cell therapy. Prior to that role, he served as the Vice President, Product Development & Portfolio Management for Barrier Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Dr. Dispersyn holds a Dr. Med. Sc. (Ph.D. in Medical Sciences), from the Faculty of Medicine, Maastricht University, Maastricht, the Netherlands, a post-graduate degree in Biomedical Imaging and a M.Sc. in Biochemistry, both from the University of Antwerp, Belgium.

Ms. Caitlin Kontulis serves as the Principal Accounting Officer, Director of Finance, Secretary and Controller at RXi Pharmaceuticals Corporation. Ms. Kontulis served as Director of Accounting at Galena Biopharma, Inc. since October 2010 and served as its Interim Principal Accounting Officer since April 14, 2011. Ms. Kontulis served as the Principal Financial Officer of RXi Pharmaceuticals Corporation. She was responsible for the administration of the RXi's accounting and SEC reporting as well as Sarbanes-Oxley implementation and compliance. From September 2007 to October 2010, she held various positions, including Senior Associate at PricewaterhouseCoopers LLP, which provides assurance, financial and business advisory services to both public and private companies. Ms. Kontulis holds a Masters degree in Accounting.

Gerrit Dispersyn serves as the Chief Development Officer for RXi Pharmaceuticals Corporation. Gerrit started at RXi Pharmaceuticals Corporation in April of 2017. Gerrit is based in the Greater New York City Area.